SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 24th, 2023 • Aspira Women's Health Inc. • In vitro & in vivo diagnostic substances • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of July 20, 2023, between Aspira Women’s Health Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
COMMON STOCKUnderwriting Agreement • August 24th, 2000 • Ciphergen Biosystems Inc • Services-commercial physical & biological research • New York
COMMON STOCK PURCHASE WARRANT ASPIRA WOMEN’S HEALTH INC.Security Agreement • July 31st, 2024 • Aspira Women's Health Inc. • In vitro & in vivo diagnostic substances
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, __________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on July ____, 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from ASPIRA WOMEN’S HEALTH INC., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Aspira Women’s Health Inc. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • February 10th, 2023 • Aspira Women's Health Inc. • In vitro & in vivo diagnostic substances • New York
Aspira Women’s Health Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
PRE-FUNDED COMMON STOCK PURCHASE WARRANT ASPIRA WOMEN’S HEALTH INC.Pre-Funded Common Stock Purchase Warrant • January 26th, 2024 • Aspira Women's Health Inc. • In vitro & in vivo diagnostic substances
THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, __________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from ASPIRA WOMEN’S HEALTH INC., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
COMMON STOCK PURCHASE WARRANT ASPIRA WOMEN’S HEALTH Inc.Common Stock Purchase Warrant • July 2nd, 2024 • Aspira Women's Health Inc. • In vitro & in vivo diagnostic substances
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, __________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, beginning on the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the three (3) year anniversary of the Initial Exercise Date (the “Termination Date”), but not thereafter, to subscribe for and purchase from Aspira Women’s Health Inc., a Delaware corporation (the “Company”), up to ______ shares of common stock, par value $0.001 per share (the “Common Stock”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Aspira Women’s Health Inc. Common Stock, par value $0.001 per share Underwriting AgreementUnderwriting Agreement • February 8th, 2021 • Aspira Women's Health Inc. • In vitro & in vivo diagnostic substances • New York
Aspira Women’s Health Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) for whom William Blair & Company, L.L.C. and Truist Securities, Inc. are acting as representatives (the “Representatives” or “you”) an aggregate of 6,000,000 shares (the “Firm Securities”) and, at the election of the Underwriters, up to 900,000 additional shares (the “Optional Securities”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Securities”). To the extent that you are the only Underwriter, all references to “each Underwriter,” “the Underwriters” or “Representatives” shall refer to just you.
COMMON STOCK PURCHASE WARRANT ASPIRA WOMEN’S HEALTH INC.Securities Agreement • January 26th, 2024 • Aspira Women's Health Inc. • In vitro & in vivo diagnostic substances
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, __________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or July ____, 2024 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on July ____, 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from ASPIRA WOMEN’S HEALTH INC., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
UNDERWRITING AGREEMENTUnderwriting Agreement • April 17th, 2018 • Vermillion, Inc. • In vitro & in vivo diagnostic substances • New York
AT THE MARKET OFFERING AGREEMENTAt the Market Offering Agreement • August 2nd, 2024 • Aspira Women's Health Inc. • In vitro & in vivo diagnostic substances • New York
ASPIRA WOMEN’S HEALTH INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of ____________, 20__ Debt SecuritiesIndenture • April 22nd, 2024 • Aspira Women's Health Inc. • In vitro & in vivo diagnostic substances • New York
PURCHASE AGREEMENTPurchase Agreement • March 30th, 2023 • Aspira Women's Health Inc. • In vitro & in vivo diagnostic substances • Delaware
THIS PURCHASE AGREEMENT (the “Agreement”), dated as of March 28, 2023, is made by and between ASPIRA WOMEN’S HEALTH INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”).
LEASE AGREEMENTLease Agreement • September 27th, 2000 • Ciphergen Biosystems Inc • Services-commercial physical & biological research
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 26th, 2024 • Aspira Women's Health Inc. • In vitro & in vivo diagnostic substances • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of January 24, 2024, between Aspira Women’s Health Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 2nd, 2024 • Aspira Women's Health Inc. • In vitro & in vivo diagnostic substances • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June 30, 2024 (the “Effective Date”), between Aspira Women’s Health Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
TECHNOLOGY TRANSFER AGREEMENT BETWEEN MOLECULAR ANALYTICAL SYSTEMS, INC. AND ISP ACQUISITION CORPORATIONTechnology Transfer Agreement • August 24th, 2000 • Ciphergen Biosystems Inc • Services-commercial physical & biological research • California
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 30th, 2023 • Aspira Women's Health Inc. • In vitro & in vivo diagnostic substances • Delaware
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 28, 2023, is entered into by and between ASPIRA WOMEN’S HEALTH INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Investor”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
Exhibit 10.10 STANDARD OFFICE LEASE - FULL SERVICE 1. BASIC LEASE PROVISIONS ("Basic Lease Provisions"): 1.1 DATE AND EFFECTIVE DATE: This Lease is dated MARCH 15, 1996, for reference purposes only. The Effective Date shall the date inserted below by...Standard Office Lease • August 24th, 2000 • Ciphergen Biosystems Inc • Services-commercial physical & biological research • California
Exhibit 10.13 CIPHERGEN BIOSYSTEMS, INC. WILLIAM E. RICH EMPLOYMENT AGREEMENT This Agreement is entered into as of August 24, 2000, (the "Effective Date") by and between CIPHERGEN BIOSYSTEMS, INC. (the "Company"), and WILLIAM E. RICH ("Executive"). 1....Employment Agreement • August 24th, 2000 • Ciphergen Biosystems Inc • Services-commercial physical & biological research • California
UNDERWRITING AGREEMENTUnderwriting Agreement • April 17th, 2018 • Vermillion, Inc. • In vitro & in vivo diagnostic substances • New York
Exhibit 10.11 STANDARD INDUSTRIAL/COMMERCIAL MULTI-TENANT LEASE--GROSS 1. BASIC LEASE PROVISIONS ("BASIC LEASE PROVISIONS"): 1.1 DATE AND EFFECTIVE DATE: This Lease is dated March 20, 1996, for reference purposes only. The Effective Date shall XXX...Standard Industrial/Commercial Multi-Tenant Lease • August 24th, 2000 • Ciphergen Biosystems Inc • Services-commercial physical & biological research
EMPLOYMENT AGREEMENTEmployment Agreement • March 21st, 2024 • Aspira Women's Health Inc. • In vitro & in vivo diagnostic substances • Connecticut
THIS EMPLOYMENT AGREEMENT (this “Agreement”) between Aspira Women’s Health Inc., a Delaware corporation (the “Company”), and Sandra Milligan (“Executive,” and together with the Company, the “Parties”) is effective as of Executive’s first day of employment (the “Effective Date”).
Exhibit 10.14 [AMERICAN INDUSTRIAL REAL ESTATE ASSOCIATION LOGO] STANDARD SUBLEASE (Short-form to be used with post 1995 AIR leases) 1. PARTIES. This Sublease, dated, for reference purposes only, August 25, 2000, is made by and between Ciphergen...Sublease Agreement • September 27th, 2000 • Ciphergen Biosystems Inc • Services-commercial physical & biological research
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • January 26th, 2024 • Aspira Women's Health Inc. • In vitro & in vivo diagnostic substances • New York
This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and Aspira Women’s Health Inc., a Delaware corporation (the “Company”), that the Placement Agent shall serve as the exclusive placement agent for the Company, on a reasonable “best efforts” basis, in connection with the proposed offering (the “Placement”) of (i) shares (the “Shares”) of common stock of the Company, par value $0.001 per share (the “Common Stock”), warrants to purchase share of Common Stock (the “Common Warrants”) and (iii) pre-funded warrants to purchase Shares (the “Pre-Funded Warrants” and together with the Shares and Common Warrants, the “Securities”). The Securities actually placed by the Placement Agent are referred to herein as the “Placement Securities.” The Shares, Pre-Funded Warrants, and the shares of Common Stock underlying the Pre-Funded Warrants will be offered and sold under the Company’s registration statement on Form S-3 (File No. 333-2
ContractWarrant Agreement • May 23rd, 2013 • Vermillion, Inc. • In vitro & in vivo diagnostic substances • New York
NEITHER THIS WARRANT, NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT (COLLECTIVELY, THE “SECURITIES”), HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER ANY STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE OFFERED, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES OR BLUE SKY LAWS, PURSUANT TO REGISTRATION OR QUALIFICATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER IS IN COMPLIANCE WITH THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES OR BLUE SKY LAWS. THIS WARRANT IS SUBJECT TO TRANSFER RESTRICTI
CIPHERGEN BIOSYSTEMS, INC. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY Rights Agent PREFERRED SHARES RIGHTS AGREEMENT Dated as of March 20, 2002Preferred Shares Rights Agreement • March 21st, 2002 • Ciphergen Biosystems Inc • Services-commercial physical & biological research • Delaware
Agreement, dated as of March 20, 2002, between Ciphergen Biosystems, Inc., a Delaware corporation, and Continental Stock Transfer & Trust Company.
LEASE AGREEMENTLease Agreement • August 24th, 2000 • Ciphergen Biosystems Inc • Services-commercial physical & biological research
Exhibit 10.9 CIPHERGEN BIOSYSTEMS, INC. PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT In consideration of my employment or continued employment by Ciphergen Biosystems (the "Company"), and the compensation now and hereafter paid to me, I hereby...Proprietary Information and Inventions Agreement • August 24th, 2000 • Ciphergen Biosystems Inc • Services-commercial physical & biological research • California
CONFIDENTIAL Aspira Women’s Health Inc. Attention: Nicole Sandford 12117 Bee Caves Road, Building III Suite 100 Austin, TX 78738Financial Advisory Agreement • July 31st, 2024 • Aspira Women's Health Inc. • In vitro & in vivo diagnostic substances • New York
The purpose of this financial advisory agreement (this “Agreement”) is to confirm the engagement of A.G.P./Alliance Global Partners (“A.G.P.”) by Aspira Women’s Health Inc. (the “Company”) to render Financial Services (as defined below) to the Company.
CIPHERGEN BIOSYSTEMS, INC FOURTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENTInvestors Rights Agreement • March 20th, 2000 • Ciphergen Biosystems Inc • California
EMPLOYMENT AGREEMENTEmployment Agreement • March 17th, 2006 • Ciphergen Biosystems Inc • Laboratory analytical instruments • Texas
THIS EMPLOYMENT AGREEMENT (“Agreement”) between Ciphergen Biosystems, Inc., a Delaware corporation (the “Company”) and Gail Page (“Executive,” and together with the Company, the “Parties”) is effective as of December 31, 2005 (the “Effective Date”).
TECHNOLOGY TRANSFER AGREEMENT BETWEEN MOLECULAR ANALYTICAL SYSTEMS, INC. AND ILLUMESYS PACIFIC, INC.Technology Transfer Agreement • August 24th, 2000 • Ciphergen Biosystems Inc • Services-commercial physical & biological research • California
EMPLOYMENT AGREEMENTEmployment Agreement • December 17th, 2014 • Vermillion, Inc. • In vitro & in vivo diagnostic substances • Texas
THIS EMPLOYMENT AGREEMENT (this “Agreement”) between Vermillion, Inc., a Delaware corporation (the “Company”), and Valerie B. Palmieri (“Executive,” and together with the Company, the “Parties”) is effective as of January 1, 2015 (the “Effective Date”). This Agreement amends and restates the Employment Agreement between the Parties, dated October 23, 2014.
Common Stock Purchase WarrantWarrant Agreement • September 15th, 2014 • Vermillion, Inc. • In vitro & in vivo diagnostic substances • New York
Vermillion, Inc., a Delaware corporation (the “Company”), for value received, hereby certifies that Liolios Group, Inc., a California corporation, or its registered assigns (the “Registered Holder”), is entitled, subject to the terms and conditions set forth below, to purchase from the Company, at any time or from time to time on or before 5:00 p.m. (New York City time) on October 31, 2015 (subject to adjustment as set forth in Section 8, the “Expiration Date”), Twenty-One Thousand (21,000) shares of Common Stock, $0.001 par value per share, of the Company (“Common Stock”), at a purchase price of $3.89 per share. The shares purchasable upon exercise of this Common Stock Purchase Warrant (this “Warrant”), and the purchase price per share, each as adjusted from time to time pursuant to the provisions of this Warrant, are hereinafter referred to as the “Warrant Shares” and the “Purchase Price,” respectively. This Warrant is one of a contemplated series of warrants (collectively, the “Comp
CONSULTING AGREEMENTConsulting Agreement • March 20th, 2013 • Vermillion, Inc. • In vitro & in vivo diagnostic substances • Texas
This Consulting Agreement (“Agreement”) is made and entered into as of the 18th day of March 2013 (the “Effective Date”), by and between Vermillion, Inc. (the “Company”) and Bruce A. Huebner (“Consultant”). The Company desires to retain Consultant as an independent contractor to perform consulting services for the Company, and Consultant is willing to perform such services, on terms set forth more fully below. In consideration of the mutual promises contained herein, the parties hereto (the “Parties”) agree as follows:
